Phase II Trial of Capecitabine (Xeloda) and Pegylated Interferon Alfa-2A (Pegasys) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma

Trial Profile

Phase II Trial of Capecitabine (Xeloda) and Pegylated Interferon Alfa-2A (Pegasys) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2012

At a glance

  • Drugs Capecitabine (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top